Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hip Fracture Pain Management
ACTRN12618001884291Phase 3Not yet recruiting
- Sponsor
- Townsville University Hospital
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ropivacaine and sodium chloride in hip fracture (2 arms), sponsored by Townsville University Hospital. Primary endpoint: Behavioural pain score. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
ropivacainesodium chloride
03
Conditions
hip fracture
Beyond the preview
Go deeper on ACTRN12618001884291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001884291.